Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aura mHSPG-targeted VDC (solid tumors)
- Development stage
- Preclinical
- Lead developer
- Aura Biosciences
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravitreal, Suprachoroidal, Intravenous
01
Overview
Aura Biosciences is developing a Virus-like Drug Conjugate (VDC) for the treatment of various solid tumors that express modified heparan sulfate proteoglycans (mHSPG). The VDC platform consists of a human papillomavirus (HPV)-derived capsid, which acts as a virus-like particle (VLP) delivery vehicle, conjugated to a cytotoxic payload. These VLPs naturally and selectively bind to tumor-associated glycosaminoglycans (GAGs), specifically mHSPGs, which are uniquely upregulated on the surface of many cancer cells compared to healthy tissue. Upon binding, the VDC is designed to deliver a cytotoxic effect that may also induce pro-immunogenic cell death, potentially stimulating a systemic anti-tumor immune response. This program represents an expansion of Aura's technology beyond its lead indications in ocular oncology and bladder cancer, aiming to leverage the high specificity of the VDC platform for the systemic treatment of mHSPG-positive solid tumors.
- Other names
- Aura VDC (solid tumors)mHSPG-targeted VDC
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on Aura mHSPG-targeted VDC (solid tumors).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aura mHSPG-targeted VDC (solid tumors).